by Plus Therapeutics | Oct 8, 2024 | GBM
#ICYMI Plus Therapeutics exhibited at the #CNS2024 Annual Meeting and Dr. John Floyd presented a ReSPECT-GBM clinical trial update Key Highlights:...
by Plus Therapeutics | Oct 2, 2024 | LM
COMING SOON 🎗️💓 In honor of #BreastCancerAwarenessMonth, we are excited to announce that we will be sharing a patient testimonial from one of our Metastatic Breast Cancer patients who was treated for Leptomeningeal Metastases through the ReSPECT-LM Clinical Trial. She...
by Plus Therapeutics | Oct 1, 2024 | GBM
Plus Therapeutics presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial, evaluating Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting yesterday. Key...
by Plus Therapeutics | Sep 30, 2024 | Uncategorized
Reminder to come by Plus Therapeutics at the @CNS_update 2024 Annual Meeting at Booth #2038 Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the...
by Plus Therapeutics | Sep 24, 2024 | Uncategorized
Today is #WorldCancerResearchDay! Join us in celebrating the incredible advancements in cancer research and the dedicated researchers working tirelessly to find new treatments and cures. Every breakthrough brings us one step closer to a cancer-free future🔬🌟🎗️ Learn...
Recent Comments